Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antigen Presenting Cells01:22

Antigen Presenting Cells

3.8K
The immune system is a complex network of cells and molecules that protects the body from foreign invaders. T cells, a type of white blood cell, play a crucial role in this process. They recognize and attack foreign substances, such as pathogens, that enter the body.
T cells require the help of antigen-presenting cells (APCs), which process foreign antigens into smaller fragments that can be recognized by T cells. These APCs are highly specialized cells that efficiently internalize antigens...
3.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.6K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.6K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

13.7K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
13.7K
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

1.8K
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
1.8K
Antigen Processing Pathways01:31

Antigen Processing Pathways

2.9K
MHC molecules are key players in the immune response, enabling T cells to recognize and respond to specific antigens. They are present on the surface of all nucleated cells in the body and are instrumental in presenting antigens to T cells and activating them. T cells recognize the MHC-antigen complex and initiate an immune response. MHC class I and MHC class II are two main types of MHC molecules, each associated with a distinct antigen processing pathway.
MHC Class I: Presenting Endogenous...
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Umbilical Cord Blood and Nonengrafting Allogeneic Cell Therapies.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Diagnosis of primary CNS lymphoma through molecular and immune biomarkers in cerebrospinal fluid (PRICELUS): a multicentre, prospective, cohort study.

The Lancet. Haematology·2026
Same author

T-cell responses to primary SARS-CoV-2 vaccination in Down syndrome - From childhood to adulthood.

Human vaccines & immunotherapeutics·2026
Same author

Boosting CAR T cell functionality with oncolytic viruses for the treatment of pediatric diffuse midline gliomas.

Molecular therapy. Oncology·2026
Same author

Author Correction: Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation.

Nature communications·2026
Same author

Natural SARS-CoV-2 infection in farmed minks <i>(Neovison vison)</i> causes lung pathology, systemic viral spread, and transmission risk, even in asymptomatic animals.

Frontiers in veterinary science·2026

Related Experiment Video

Updated: May 6, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

17.7K

Harnessing dendritic cells for tumor antigen presentation.

Stefan Nierkens1, Edith M Janssen

  • 1Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Geert Grooteplein 28, Nijmegen 6525 GA, The Netherlands. edith.janssen@cchmc.org.

Cancers
|November 12, 2013
PubMed
Summary

Harnessing dendritic cells (DCs) for cancer therapy shows promise. This review examines challenges in loading DCs with tumor antigens, a key step for effective anti-tumor T cell responses.

More Related Videos

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.9K
Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo
10:35

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Published on: February 5, 2021

3.0K

Related Experiment Videos

Last Updated: May 6, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

17.7K
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.9K
Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo
10:35

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Published on: February 5, 2021

3.0K

Area of Science:

  • Immunology
  • Cancer Therapy
  • Cellular Biology

Background:

  • Dendritic cells (DCs) are critical antigen-presenting cells for initiating anti-tumor T cell immunity.
  • Therapeutic strategies utilizing DCs for cancer treatment are under active investigation.
  • Current ex vivo DC-based therapies face challenges in clinical efficacy and logistical complexity.

Purpose of the Study:

  • This review critically analyzes obstacles in current dendritic cell-based cancer immunotherapies.
  • It specifically addresses the pivotal step of in vitro tumor antigen loading onto DCs.
  • The focus is on improving the priming of tumor-specific CD8+ and CD4+ T cells.

Main Methods:

  • This is a review article, synthesizing existing research on dendritic cell biology and cancer immunotherapy.
  • It examines literature pertaining to antigen loading techniques for ex vivo-generated DCs.
  • The review focuses on the in vitro aspects of DC manipulation for therapeutic purposes.

Main Results:

  • While ex vivo-generated and tumor-antigen loaded DCs are feasible, significant hurdles remain.
  • The efficiency and effectiveness of in vitro DC antigen loading directly impact T cell priming.
  • Overcoming these obstacles is essential for enhancing clinical trial success rates.

Conclusions:

  • Improving the in vitro loading of dendritic cells with tumor antigens is crucial for advancing DC-based cancer immunotherapy.
  • Addressing current challenges can lead to more effective and cost-efficient cell therapies.
  • Further research into optimal antigen loading methods will enhance anti-tumor T cell responses.